Splicing Factor Activity for Detecting and Treating Cancer (Yissum)

code: 6-2009-2323

Rotem Karni, HUJI, Faculty of Medicine, Cellular biochemistry and human genetics

Splicing factor levels predict patient prognosis and indicate drug efficacy

Categories	Oncology/Cancer, RNA/Protein/Diagnosis, Biomarkers
Development Stage	Proof of concept in vitro and in small animals
Patent Status	Patent filed in the United States
Market	Cancer testing is currently one of the most important growth opportunities diagnostics segment. The worldwide market for in vitro cancer diagnosis is estimated in few billions.

Highlights

- Detection of the levels of specific splicing factors used to indicate presence of cancer and cancer outcome.
- Successfully demonstrated ability to predict the survival time of patients with brain tumors and to detect the metastatic stages of breast cancer
- Down-regulation of specific splicing factors inhibits glioblastoma development and metastasis of breast cell into the lungs in mouse xenograft models
- Splicing factor levels are better prognostic markers than markers currently in use.
- Highly sensitive diagnostic tool
- New treatment approach

Our Innovation

Novel approach to diagnosing cancer and a patient's sensitivity to specific drugs using the levels in the body of certain splicing factors as markers; local down-regulation of splicing factors by Antisense RNA oligos for the treatment of glioblastoma and metastatic breast cancer

Key Features

- Accurate prediction of tumor stage and cancer severity
- More Accurate diagnosis for efficient treatment **to prevent suffering** of cancer patients
- New Efficient treatment for glioblastoma and metastatic breast cancer

Development Milestones

Seeking funding for ongoing research, further animal trials, and accumulation of patient data

The Opportunity

Applications in cancer diagnosis and a new treatment for glioblastoma and metastatic breast cancer

Contact for more information:

Shoshana Keynan ✉, VP, Head of Business Development, Healthcare, +972-2-6586683

Yissum Research Development Company of the Hebrew University of Jerusalem
Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390
Israel Telephone: 972-2-658-6688, Fax: 972-2-658-6689